--- title: "Amass — Scientific intelligence you can verify" description: "Scientific intelligence built on the Amass *Core architecture: papers, trials, drugs, genes, patents, regulatory records and the live web, cited to source." url: https://amass.tech --- # Amass — Scientific intelligence you can verify Answers are only as useful as the evidence behind them # Scientific intelligence you can verify. Amass searches papers, clinical trials, drugs, genes, patents, regulatory records and the live web. Every answer stays connected to its sources, so you can inspect the evidence behind it. [Try free](https://amass.tech/try)[Book a demo](https://amass.tech/demo) Free plan, $0 forever. No card required. [01App Ask a research question and watch it work: every claim cited, and what it read but didn’t cite shown too.](#cr-panel-app) [02MCP Amass inside the tools you already use: Claude, ChatGPT, Claude Code and Codex, over MCP.](#cr-panel-mcp) [03API Build on the engine: typed, cited responses you can program against.](#cr-panel-api) [See the App →](https://amass.tech/app) One question, three ways in: the app with its trace and citations, an assistant calling the Amass tool over MCP, and the API returning the record. Each answer cites the ID of the record behind it, such as a PMID, NCT ID or patent number, in the Amass app, in Claude and ChatGPT over MCP, or from the API. ## A fluent answer is not a checkable one. Amass returns each answer with its sources. Each claim carries an identifier that opens the record it came from: a DOI, an NCT ID, a ChEMBL ID, a patent number or a regulatory application number. peer-reviewed papers 43M+ BioMedCore scholarly papers 233M+ ScholarCore\* patent filings 170M+ PatentCore one schema FDA + EMA RegulatoryCore drugs & molecules 22K+ DrugCore clinical trials 1.2M+ TrialCore human genes 43K+ GeneCore real-time web sources Live WebCore\* \* In the app; the API and MCP serve the other six. 1. **01**ScatterYour sources sit on separate platforms 2. **02**DriftThe same question gets different answers over time 3. **03**ConvergeAmass traces each claim to the record it came from 4. **04**CiteEvery answer shows its sources, so the team shares one picture Research holds the answer ## Evidence is scattered across teams, tools and documents. ## Reasoning drifts across data, teams and time. ## Amass resolves it to the record. Every claim cited to source. One question about a medicine can touch a journal article, a trial registry, a patent and a regulatory label, then the slides and emails a team writes about them. None of them links to the others. Each answer starts from whichever documents someone found. A slide repeats one reading of a result, an email another, and the readings drift as they are copied forward. None says where its figure came from. Behind every claim sits a record, held in the \*Core for that kind of source. A slide or an email is not a record, so Amass reads it but never cites it. JournalBioMedCore [10.1056/NEJMoa2413258](https://doi.org/10.1056/NEJMoa2413258) RegistryTrialCore [NCT04822181](https://clinicaltrials.gov/study/NCT04822181) PatentPatentCore [US-2025375504-A1](https://patents.google.com/patent/US20250375504A1/en) LabelRegulatoryCore [NDA 215256](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256) SlideQ3 review, slide 12 not a source EmailRe: MASH readout, v7 not a source Each reference opens its record. What was read but not cited stays on a list of its own, so the team works from one picture it can check. The platform ## One evidence base for researchers, agents and apps. One record, served three ways: as the app writes it, as the API returns it and as an MCP tool call fetches it. The app searches all eight \*Cores; the API and the MCP serve six. 1. Grounded research across every surfaceUse Amass in the app, through agents, or directly via API and MCP. 2. One engine over eight \*Cores\*Cores for papers, trials, drugs, genes, patents, and FDA + EMA regulatory records. 3. Every claim traceable to sourceAnswers, workflows and outputs stay linked to the underlying evidence. Researchers Apps & Agents Developers 8 \*Cores App MCP API Amass \*Core architecture BioMedCore 43M+ ScholarCore 233M+ PatentCore 170M+ RegulatoryCore 7K+ DrugCore 22K+ TrialCore 1.2M+ GeneCore 43K+ WebCore Live Provenance & citations External data providers PubMedLiteraturePMCLiteratureCrossrefLiteratureUSPTOPatentsEPOPatentsWIPOPatentsSureChEMBLPatentsFDARegulatoryEMARegulatoryClinicalTrials.govTrialsWHO ICTRPTrialsHGNCGenes & moleculesEnsemblGenes & moleculesUniProtGenes & moleculesChEMBLGenes & moleculesWebWeb Connect your own data SharePointYour dataOneDriveYour dataGoogle DriveYour dataDatabricksYour dataS3 / BlobYour dataNetwork drivesYour data [See the three surfaces →](https://amass.tech/product) MCP ## Inside the assistant you already use. Amass runs inside Claude, ChatGPT, Claude Code and Codex over the Model Context Protocol (MCP). The assistant calls an Amass tool, and the answer comes back with the identifiers. [Set it up →](https://amass.tech/mcp) ClaudeChatGPTClaude CodeCodexAmass connected Which Lp(a)-lowering programs are in phase 3? amass`search_amass_trialcore_records`Completed `query: "lipoprotein(a) cardiovascular outcomes"``phase: "PHASE3"` [NCT04023552](https://clinicaltrials.gov/study/NCT04023552)Lp(a)HORIZON · COMPLETED · Novartis Pharmaceuticals [NCT05581303](https://clinicaltrials.gov/study/NCT05581303)OCEAN(a)-Outcomes · ACTIVE\_NOT\_RECRUITING · Amgen Two phase 3 programs: Lp(a)HORIZON (NCT04023552) has completed, and OCEAN(a)-Outcomes (NCT05581303) is active and no longer recruiting. Reply… An assistant calling Amass’s TrialCore search tool, and the two trial records it hands back. API ## The same record, as a response. Build on the engine with one REST API across six cross-linked \*Cores. Each response is typed and carries the identifiers of its sources. GET`https://api.amass.tech/api/v1/cores/trialcore/records?query=NCT04023552&limit=1`Authorization: Bearer •••• 200 OKapplication/json {"data": \[{"nctId": "[NCT04023552](https://clinicaltrials.gov/study/NCT04023552)","acronym": "Lp(a)HORIZON","phase": "PHASE3","overallStatus": "COMPLETED","sponsorName": "Novartis Pharmaceuticals","enrollment": 8323,"completionDate": "2026-07-16","referencesBiomedCore": \[ "AMBC\_…", … \],}\]} One trial record from the documented TrialCore records path, as the API returns it. [API docs →](https://platform.amass.tech/documentation/getting-started/overview) ## Used by people at > Amass gives our investment team one place to validate science, patents, and trials, with citations we can stand behind in committee. Luis Toledo Senior Scientist, Novo Holdings SeedLab ## Your research, cited to source. Start free in the app or with an API key. Enterprise deployments add an SLA, single-tenant hosting and onboarding support. [Try free](https://amass.tech/try)[Book a demo](https://amass.tech/demo) Data No training on your data Hosting EU-hosted, enterprise Isolation Tenant-isolated by architecture Certification ISO 27001, SOC 2, NIS2: in motion